The FDA has accepted a once-daily pill for moderate-to-severe plaque psoriasis under Priority Review, setting a target decision date in the first quarter of 2027 for a drug that cleared skin in about seven of ten patients in two large trials.
Takeda announced the acceptance on Monday for zasocitinib, known in development as TAK-279. It is an oral tyrosine kinase 2 inhibitor, a class that works inside immune cells rather than blocking a signaling protein from outside the way injected biologics do. Takeda says the compound has more than a million-fold greater selectivity for TYK2 than for the related JAK1, JAK2 and JAK3 enzymes, based on laboratory data.
For people whose psoriasis is moderate to severe, the practical question has been a trade-off. Existing oral options are generally less effective than injections, and the most effective options usually mean a needle every few weeks or months. A pill that performs closer to injection-level clearance would change that calculation.
Nothing changes this week. Zasocitinib is not approved anywhere in the world, and no prescription is available.
About Seven in Ten Reached Clear or Almost Clear Skin
The filing rests on two global Phase 3 trials, LATITUDE PsO 3001, which enrolled 693 participants, and the second pivotal trial, which enrolled 1,108. Both ran across 21 countries and used both placebo and an active comparator, the older oral drug apremilast.
On the co-primary measures at week 16, 71 percent and 69 percent of zasocitinib patients reached clear or almost clear skin on the physician assessment scale, against 11 percent and 13 percent on placebo and 32 percent and 30 percent on apremilast. For the 75 percent skin-improvement threshold, results were 76 percent and 71 percent, against 12 percent on placebo in both trials and 37 percent and 33 percent on apremilast.
Deeper clearance held up. About 61 percent and 52 percent reached 90 percent improvement, and 33 percent and 25 percent reached completely clear skin. Response appeared early, with measurable separation from placebo by week 4, and continued improving through weeks 24 and 52. Takeda said the co-primary endpoints and all 44 ranked secondary endpoints were met across both trials.
Scalp, Nails, Palms and Soles Carry Outsized Daily Burden
Total body coverage is how psoriasis gets scored. It is not how patients experience it. A patch on the scalp that flakes onto a work shirt, or plaques on the soles that make standing a shift painful, can dominate someone's life even when the percentage of skin involved looks modest.
Those sites were measured. Scalp clearance reached 77 percent and 74 percent on zasocitinib, against 7 percent and 13 percent on placebo and 42 percent and 30 percent on apremilast. Nail severity scores fell by 7.1 and 8.6 points from baseline, compared with a 1.8-point worsening and a 1.4-point improvement on placebo. Clearance on the hands and feet reached 71 percent and 69 percent, against 22 percent and 10 percent on placebo and 44 percent and 43 percent on apremilast.
Andy Plump, Takeda's president of research and development, said "there remains a need for highly effective oral therapies" that address the harder manifestations of psoriasis, including scalp involvement.
Two caveats accompany those figures. The hands-and-feet comparison was not multiplicity controlled, so Takeda states that the apremilast contrast there is descriptive rather than a formal statistical win. And these site-specific outcomes were secondary measures, not what the trials were designed around.
The Comparison Inside the Filing and the One Outside It
The comparator matters as much as the numbers. Apremilast is an older oral drug with modest clearance rates, and beating it is a lower bar than beating a modern injectable biologic. Neither pivotal trial tested zasocitinib against ustekinumab, secukinumab, risankizumab or any other injection.
A separate head-to-head trial has reported, though it is not among the studies Takeda lists as supporting this application. In LATITUDE Atlas, zasocitinib beat deucravacitinib on complete skin clearance at week 16, the trial's primary endpoint, and on key secondary measures, according to topline results the company announced in June. Deucravacitinib is the TYK2 inhibitor already on the market, and it is also an oral drug, so that result does not answer how zasocitinib compares with injections either.
On safety, the most common adverse events across both pivotal trials were upper respiratory infection at 10.1 percent, acne at 6.5 percent, and nasopharyngitis at 6.2 percent. Takeda reported no new safety signals. Longer-term data came from an open-label extension in about 2,100 adults dosed for up to 156 weeks, which is useful but neither randomized nor blinded.
TYK2 belongs to the JAK enzyme family, and the older, less selective drugs in that family carry class warnings for serious infections, blood clots, and cardiovascular events. Takeda's selectivity claim rests on in vitro data. What warnings the FDA ultimately applies to the label is not yet known, and that detail will matter to patients with cardiovascular risk factors. All the trials were funded and run by Takeda, which has also filed in Europe, where the European Medicines Agency has begun its review.
Cost, Coverage and a Crowded Oral Shelf
If zasocitinib is approved, it enters a shelf that got more crowded this year. On March 18 the FDA approved icotrokinra, an oral IL-23 receptor blocker from Johnson & Johnson, for patients 12 and older weighing at least 40 kilograms, on the strength of a program that did include head-to-head comparisons against active drugs.
More competition among orals can eventually help patients on price and prior authorization, but new branded specialty drugs typically launch expensive and arrive with step-therapy requirements. Plans often ask patients to fail a cheaper option first.
Patients with moderate-to-severe disease who are frustrated with current treatment have useful things to do now rather than in 2027. They can ask a dermatologist whether an already-approved oral or biologic fits, make sure scalp, nail, and palmoplantar involvement is documented in the chart because those findings support coverage for systemic therapy, and ask about manufacturer patient-assistance programs.
No one should stop a current psoriasis treatment in anticipation of a drug that does not exist yet. Flares after stopping systemic therapy can be severe, and rebound is a real risk with some agents. The next firm date is the FDA action target in the first quarter of 2027, and approval is not guaranteed.
Key Questions Answered
What happened? The FDA accepted Takeda's new drug application for zasocitinib under Priority Review for adults with moderate-to-severe plaque psoriasis, with a target decision date in the first quarter of 2027.
How well did it work? About 71 percent and 69 percent of patients across the two pivotal trials reached clear or almost clear skin at week 16, against 11 percent and 13 percent on placebo and about 30 percent on apremilast.
Can patients get it now? No. Zasocitinib is investigational and has not been approved by any regulator.
Was it compared with injectable biologics? No. The active comparator in both pivotal trials was apremilast, an older oral drug. A separate trial found zasocitinib superior to deucravacitinib, which is also a pill.
What side effects were reported? Upper respiratory infection in 10.1 percent of patients, acne in 6.5 percent, and nasopharyngitis in 6.2 percent, with no new safety signals reported by the company.
Does it help scalp and nail psoriasis? Scalp clearance reached 74 to 77 percent and nail severity scores improved by about 7 to 9 points, though these were secondary measures rather than the trials' main goals.
What should patients do in the meantime? Discuss currently approved oral and injectable options with a dermatologist, and do not stop an existing treatment in anticipation of a drug still under review.
